| Literature DB >> 18236489 |
Jose M Munoz-Olaya1, Xavier Matabosch, Carmen Bedia, Meritxell Egido-Gabás, Josefina Casas, Amadeu Llebaria, Antonio Delgado, Gemma Fabriàs.
Abstract
A novel mechanism-based dihydroceramide desaturase inhibitor (XM462) in which the substrate C5 methylene group is replaced by a sulfur atom is reported. Dihydroceramide desaturase inhibition occurred both in vitro and in cultured cells with IC(50) values of 8.2 and 0.78 microM, respectively, at a substrate concentration of 10 microM. In vitro experiments showed that XM462 produced a mixed-type inhibition (K(i)=2 microM, alpha=0.83). LC-MS analyses showed that accumulation of endogenous dihydroceramides occurred in cells upon treatment with XM462 in serum-free medium, whereas ceramides built up in controls. In addition, XM462 was found to be metabolised to its 1-glucosyl and 1-phosphocholine derivatives, and to the products of N-deacylation and reacylation with palmitoyl and stearoyl groups. In Jurkat A3 cells cultured in serum-free medium, viability, as the percentage of trypan blue unstained cells in total cells, was reduced upon XM462 treatment (5 microM, 24 h), but not in controls. The interest of this compound is discussed.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18236489 DOI: 10.1002/cmdc.200700325
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466